Close Menu
The Business TimesThe Business Times
  • Home
  • News
  • Business
  • Finance
  • Economy
  • Markets
  • Investing
  • Real Estate
  • Crypto
  • Fintech
  • Forex
  • More
    • Politics
    • Web Stories
    • Spotlight
    • Press Release
What's On

Top 25 Dividend Stock Opportunities For September 2026

1 September 2026

Cango Inc. (CANG) Q2 2026 Earnings Call Transcript

1 September 2026

Betmakers Technology Group Ltd (TPBTF) Q4 2026 Earnings Call Transcript

1 September 2026

SPHB ETF: High Beta Means Strong Upside Capture But Weak Risk-Adjusted Returns;, Hold

1 September 2026

Shui On Land Limited 2026 Q2 – Results – Earnings Call Presentation (OTCMKTS:SOLLY) 2026-08-31

1 September 2026
Facebook X (Twitter) Instagram
Business Tuesday, Sep 1
The Business TimesThe Business Times
Newsletter
  • Home
  • News
  • Business
  • Finance
  • Economy
  • Markets
  • Investing
  • Real Estate
  • Crypto
  • Fintech
  • Forex
  • More
    • Politics
    • Web Stories
    • Spotlight
    • Press Release
The Business TimesThe Business Times
Home » Nomura Holdings, Inc. (NMR) Analyst/Investor Day Transcript
News

Nomura Holdings, Inc. (NMR) Analyst/Investor Day Transcript

thebusinesstimes.co.ukBy thebusinesstimes.co.uk4 June 20261 Views
Facebook Twitter LinkedIn Reddit Telegram WhatsApp Pinterest Tumblr VKontakte Email
Nomura Holdings, Inc. (NMR) Analyst/Investor Day Transcript
Share
Facebook Twitter LinkedIn Pinterest Email

Kentaro Okuda
President, Group CEO, Representative Executive Officer & Director

This is Kentaro Okuda, Group CEO. Thank you very much for taking time out of your busy schedules to join our Investor Day today.

Let me begin with the most important point. We are significantly raising our numerical targets for 2030, ROE to 10% to 12% or more and income before income taxes to over JPY 750 billion by 2030. Following my presentation, the heads of our 4 divisions will each present their strategies. So in my part, I would like to explain the progress we have made in transforming our business model, the upward revision of our numerical targets for 2030 and our growth strategy and organizational foundation aimed at achieving those targets.

First, I’d like to review the progress we have made so far in transforming our business model. In the previous fiscal year, net revenue totaled JPY 2,167.7 billion. Income before income taxes was JPY 539.8 billion, and net income was JPY 362.1 billion. This represented both higher revenues and higher profits. Net income reached a record high for the second consecutive year. Income before income taxes and ROE are progressing faster than the targets we initially set when formulating our management vision for 2030. Each KPI is also progressing at a

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram WhatsApp

Related Articles

Top 25 Dividend Stock Opportunities For September 2026

Cango Inc. (CANG) Q2 2026 Earnings Call Transcript

Betmakers Technology Group Ltd (TPBTF) Q4 2026 Earnings Call Transcript

SPHB ETF: High Beta Means Strong Upside Capture But Weak Risk-Adjusted Returns;, Hold

Shui On Land Limited 2026 Q2 – Results – Earnings Call Presentation (OTCMKTS:SOLLY) 2026-08-31

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe Hypertriglyceridemia Transcript

Pzena Focused Credit Opportunities Q2 2026 Commentary

Virtus KAR Small-Cap Growth Fund Q2 2026 Commentary

Ensurge Micropower ASA (ENMPF) Q2 2026 Earnings Call Transcript

Editors Picks

Cango Inc. (CANG) Q2 2026 Earnings Call Transcript

1 September 2026

Betmakers Technology Group Ltd (TPBTF) Q4 2026 Earnings Call Transcript

1 September 2026

SPHB ETF: High Beta Means Strong Upside Capture But Weak Risk-Adjusted Returns;, Hold

1 September 2026

Shui On Land Limited 2026 Q2 – Results – Earnings Call Presentation (OTCMKTS:SOLLY) 2026-08-31

1 September 2026

Subscribe to News

Get the latest finance and business news and updates directly to your inbox.

Latest Posts

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe Hypertriglyceridemia Transcript

31 August 2026

Pzena Focused Credit Opportunities Q2 2026 Commentary

31 August 2026

Virtus KAR Small-Cap Growth Fund Q2 2026 Commentary

31 August 2026
Facebook X (Twitter) Pinterest WhatsApp TikTok Instagram
© 2026 The Business Times. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.